| Autor: |
Stefania Angela Di Fusco, Edoardo Gronda, Edoardo Mocini, Fabiana Lucà, Irma Bisceglia, Leonardo De Luca, Pasquale Caldarola, Manlio Cipriani, Marco Corda, Alfredo De Nardo, Giuseppina Maura Francese, Cosimo Napoletano, Alessandro Navazio, Carmine Riccio, Loris Roncon, Emanuele Tizzani, Federico Nardi, Stefano Urbinati, Serafina Valente, Michele Massimo Gulizia, Domenico Gabrielli, Fabrizio Oliva, Giuseppe Imperoli, Furio Colivicchi |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
European heart journal supplements : journal of the European Society of Cardiology. 24 |
| ISSN: |
1520-765X |
| Popis: |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and empagliflozin, first developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been demonstrated to improve prognosis in patients with heart failure and reduced ejection fraction (HFrEF) regardless of the presence of diabetes. Since these drugs have only recently been included among the four pillars of HFrEF treatment, cardiologists are still unfamiliar with their use in this setting. This article provides an up-to-date practical guide for the initiation and monitoring of patients treated with SGLT2 inhibitors. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
